RecruitingPhase 2NCT07311200

A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of D-2570 in Patients With Active Systemic Lupus Erythematosus

Sponsor

InventisBio Co., Ltd

Enrollment

120 participants

Start Date

Feb 12, 2026

Study Type

INTERVENTIONAL

Conditions

Active Systemic Lupus Erythematosus

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called D-2570 and a drug called D-2570 Placebo for people with active systemic lupus erythematosus. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGD-2570

Participants will be assigned to one of the following groups: Group A, Group B, Group C, or the placebo control group.

DRUGD-2570 Placebo

D-2570 Placebo

Locations(1)

Linfen Central Hospital

Linfen, Jiangxi, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07311200